MAT2A and hepatocellular carcinoma: The enhanced expression and activity of MAT2A results in an elevated production of SAM and has been associated with tumour progression in liver cancer (78), hepatocellular carcinoma (HCC) (79, 80) and colorectal cancer (81, 82).